STOCK TITAN
  1. Home
  2. News
  3. MNPR

Monopar Therapeutics Inc - MNPR STOCK NEWS

Welcome to our dedicated news page for Monopar Therapeutics (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Monopar Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Monopar Therapeutics's position in the market.

News
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
Rhea-AI Summary
Monopar Therapeutics Inc. announced that its abstract on the preclinical data for its radiopharmaceutical program MNPR-101-Zr has been selected for a presentation at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting in Toronto, Canada. The event, scheduled from June 8 to June 11, 2024, is a significant platform for showcasing innovative treatments for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
Rhea-AI Summary
Monopar Therapeutics Inc. files a provisional patent application for MNPR-101 radiopharma optimization findings, aiming to enhance the clinical profile of the construct and strengthen intellectual property. The company focuses on developing innovative cancer treatments, with recent advancements in the MNPR-101-Zr construct and Phase 1 dosimetry clinical trial initiation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.58%
Tags
none
-
News
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
Rhea-AI Summary
Monopar Therapeutics Inc. announces the activation of its Phase 1 dosimetry clinical trial for MNPR-101-Zr, a radiopharmaceutical imaging agent targeting uPAR in various cancers. The trial, led by Professor Rodney Hicks at MTIC, aims to evaluate safety and dosimetry in advanced cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.36%
Tags
clinical trial
News
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
Rhea-AI Summary
Monopar Therapeutics Inc. (Nasdaq: MNPR) reported its fourth quarter and full-year 2023 financial results, along with recent developments. The company announced the initiation of a Phase 1 dosimetry clinical trial for its MNPR-101 Radiopharmaceutical Program targeting uPAR. Positive preclinical data support the potential of MNPR-101 to provide significant clinical benefits. Monopar also shared biodistribution data using therapeutic radioisotopes conjugated to MNPR-101, showing promising results in tumor elimination. The company is enrolling patients in the fifth dose level cohort for its Camsirubicin Phase 1b Dose-Escalation Trial. Financially, Monopar reported $7.3 million in cash and short-term investments as of December 31, 2023, with a net loss of $1.8 million for the fourth quarter of 2023. Research and Development expenses decreased, while General and Administrative expenses slightly increased.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.6%
Tags
earnings
-
News
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
Rhea-AI Summary
Monopar Therapeutics Inc. (MNPR) announces positive preclinical imaging data for its proprietary uPAR targeting agent MNPR-101, demonstrating highly preferential uptake in tumors. The data support the tumor-targeting ability of MNPR-101 and explain the elimination of tumors observed in previous studies. Monopar also received clearance to begin a Phase 1 dosimetry clinical trial for MNPR-101-Zr in advanced cancer patients, reinforcing its efforts in developing radiodiagnostic and radiotherapeutic treatments for uPAR-positive cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.06%
Tags
none
-
News
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
Rhea-AI Summary
Monopar Therapeutics Inc. announced that Professor Rodney Hicks will lead the MNPR-101-Zr Phase 1 dosimetry clinical trial in advanced cancer patients using advanced PET/CT scanners. The trial aims to develop innovative treatments for pancreatic cancer and triple negative breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.37%
Tags
clinical trial
News
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
Rhea-AI Summary
Monopar Therapeutics Inc. (MNPR) announces promising preclinical imaging and therapeutic efficacy data for its MNPR-101 radiopharmaceutical program targeting cancers expressing uPAR, including triple-negative breast, colorectal, and pancreatic cancers. The company's in-house team successfully increased tumor uptake while minimizing healthy tissue uptake, showcasing high specificity and durable tumor uptake. Preclinical data demonstrate compelling anti-tumor benefits with near complete tumor elimination in human tumor xenograft mouse models. Monopar received clearance to begin a Phase 1 dosimetry clinical trial for MNPR-101-Zr in advanced cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
96.49%
Tags
clinical trial
-
News
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
Rhea-AI Summary
Monopar Therapeutics Inc. (MNPR) receives clearance for a Phase 1 dosimetry trial of MNPR-101-Zr, a radiopharmaceutical targeting uPAR-expressing tumors. The trial aims to assess tumor uptake, biodistribution, and safety using PET imaging. Positive preclinical results support the potential for MNPR-101 as a targeted radiopharmaceutical for various advanced cancer indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
95.04%
Tags
clinical trial
-
News
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
Rhea-AI Summary
MNPR - Monopar Therapeutics Inc. Announces Third Quarter 2023 Financial Results and Recent Developments including MNPR-101 Radiopharma Program entering First-in-Human Studies and Camsirubicin Phase 1b Trial Efficacy and Safety Data. MNPR-101 is a highly selective antibody against uPAR, showing promising results in preclinical studies. Camsirubicin Phase 1b Trial has treated patients with advanced soft tissue sarcoma, with positive results and no observed dose-limiting toxicity. MNPR-202, a camsirubicin analog, shows encouraging preclinical results. The third quarter ended with $8.5 million in cash and a net loss of $2.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
earnings
News
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
Rhea-AI Summary
Monopar Therapeutics Inc. will present data from its ongoing Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma at the 2023 Connective Tissue Oncology Society Annual Meeting. So far, 9 out of 14 patients have had stable disease after camsirubicin treatment, and 3 patients experienced a 20% tumor size reduction. No dose-limiting toxicity has been observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.91%
Tags
clinical trial
Stock MNPR logo
Monopar Therapeutics Inc

Nasdaq:MNPR

MNPR Rankings

#5335 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

MNPR Stock Data

13.63M
8.31M
52.35%
1.55%
0.98%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Wilmette

About MNPR

monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.